Clinical trials: Virus
Chronic Hepatitis C, Hepatitis C
Post-marketing Surveillance of HIV-infected Patients With Chronic Hepatitis C Treated With PegIntron Pen and Rebetol (Study P04584)
The objective of the study was to assess the safety and efficacy of peginterferon alfa-2b (PEG-IFN alfa-2b) and ribavirin (RBV) administered to participants coinfected with Human Immunodeficiency Virus (HIV) and Hepatitis C Virus…
- Conditions
- Chronic Hepatitis C, Hepatitis C, HIV Infections
- Trial name
- NCT00736242
- Testing
- PEG-IFN alfa-2b, RBV
- Volunteers
- 232 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV
Changes in Triglyceride and Other Lipids (Levels of Fats Found in Blood) When Taking Darunavir Compared to Atazanavir in HIV-infected Patients That Have Never Received Treatment
The purpose of this research study is to compare changes in triglyceride and other lipids (levels of fats found in the blood) from Baseline (Day 1) to Week 12 for darunavir/ritonavir 800/100 mg once daily versus…
- Trial name
- NCT00757783
- Testing
- ritonavir, darunavir, emtricitabine [FTC]/tenofovir [TDF]
- Where
- 15 sites in United States
- Volunteers
- 68 people
- Sponsor
- Tibotec, Inc
Blastic Plasmacytoid Dendritic Cell Neoplasm, Hepatosplenic T-Cell Lymphoma
Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
This phase II trial studies how well nivolumab works in treating patients with peripheral T-cell lymphoma that has come back after a period of improvement or that does not respond to treatment.
- Conditions
- Blastic Plasmacytoid Dendritic Cell Neoplasm, Hepatosplenic T-Cell Lymphoma, HTLV-1 Infection, NK-Cell Lymphoma, Unclassifiable
- Trial name
- NCT03075553
- Testing
- Laboratory Biomarker Analysis, Nivolumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Mayo Clinic
HIV (Human Immunodeficiency Virus)
mVIP (Use of mHealth Technology for Supporting Symptom Management in Underserved Persons Living With HIV)
The goal of this study is to facilitate the dissemination and implementation of patient centered outcomes research using mHealth technology to improve self-management of adverse symptoms in persons living with HIV/AIDS (PLWH).
- Trial name
- mVIP (NCT02897141)
- Testing
- Health Management App with symptom strategies, Control App
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Columbia University
Influenza
Sanofi H1N1 Influenza Vaccine Administered at Two Dose Levels in Adult and Elderly Populations
The purpose of this study is to assess the safety and the body's immune response (body's defense against disease) to an experimental H1N1 influenza vaccine in healthy adult and elderly populations.
- Trial name
- NCT00943631
- Testing
- Inactivated H1N1 Vaccine
- Where
- 3 sites in United States
- Volunteers
- 406 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Respiratory Syncytial Viruses
Phase 2a Respiratory Syncytial Virus (RSV) Human Challenge Study of Clesrovimab (MK-1654) in Healthy Participants (MK-1654-005)
The primary objective of this study is to determine if a single intravenous (IV) dose of clesrovimab when administered at 1 of 4 dose levels results in a reduction in viral load after intranasal inoculation (with RSV A Memphis…
- Trial name
- NCT04086472
- Testing
- Clesrovimab, RSV-A Memphis 37b
- Where
- United Kingdom
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Alcohol Use Disorder, HIV/AIDS
Understanding and Intervening With Heavy Drinking Among Patients With HIV and HCV
Among patients with HIV, especially those also infected with HCV, heavy drinking is associated with significant risks to health.
- Conditions
- Alcohol Use Disorder, HIV/AIDS, Hepatitis C, Binge Drinking
- Trial name
- NCT03652675
- Testing
- Intervention: (Clinician's Guide + HealthCall for HIV/HCV)
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- New York State Psychiatric Institute
Drug Use Disorders, Hepatitis C
Community-Based, Client-Centered Prevention Homes to Address the Rural Opioid Epidemic- Aim 3
The goal of this study was to effectively use a client-centered community-based intervention to engage people who inject drugs (PWIDs) in healthcare that helps reduce risky behaviors and lower infectious disease risks.
- Conditions
- Drug Use Disorders, Hepatitis C, Harm Reduction, Opioid-use Disorder
- Trial name
- NCT04268173
- Testing
- Community-Based, Client-Centered Prevention Home
- Where
- 6 sites in United States
- Volunteers
- 343 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Covid-19
CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients
This is a phase 3, randomized, placebo controlled, double-blind, multicenter, stratified study of CPI-006 plus standard of care (SOC) versus placebo plus SOC in mild to moderately symptomatic hospitalized Covid-19 patients with…
- Trial name
- NCT04734873
- Testing
- CPI-006 2 mg/kg + SOC, CPI-006 1 mg/kg + SOC
- Where
- 91 sites in United States, Argentina and 10 more
- Volunteers
- 46 people
- Sponsor
- Corvus Pharmaceuticals, Inc.
Human Immunodeficiency Virus (HIV)
Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278LA, for Pre-Exposure Prophylaxis
This is a multi-site, double-blinded, two-arm, two:one, randomized, trial comparing the safety of an intramuscular (IM) injection of TMC278 LA to a placebo given once every eight weeks over a 40 week period among sexually active…
- Trial name
- TMC278LA (NCT02165202)
- Testing
- Rilpivirine
- Where
- 4 sites in United States, South Africa and 1 more
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- PATH
Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma
Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas
The purpose of this study is to evaluate how safe and effective the combination of two different drugs (brentuximab vedotin and rituximab) is in patients with certain types of lymphoma.
- Conditions
- Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma
- Trial name
- NCT01805037
- Testing
- brentuximab vedotin, rituximab, laboratory biomarker analysis
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Northwestern University
Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma
The goal of this clinical research study is to learn if the combination of oblimersen sodium and rituximab can help to shrink or slow the growth of the tumor in patients with B-cell non-Hodgkin's lymphoma who have not responded…
- Conditions
- Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma
- Trial name
- NCT00054639
- Testing
- oblimersen sodium, rituximab, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- National Cancer Institute (NCI)
This is a Pilot Study Which Aims to Assess the Validity and Applicability of Lateral Flow Assays (LFAs) Which Can be Used as a Point of Care Test for COVID-19, Covid19
The LAVA (Lateral Flow Antigen Validation and Applicability) Study for COVID-19
This is a pilot study which aims to assess the validity and applicability of lateral flow assays (LFAs) which can be used as a point of care test for COVID-19.
- Trial name
- LAVA (NCT04629157)
- Testing
- Innova Lateral Flow Device
- Where
- 2 sites in United Kingdom
- Volunteers
- 400 people
- Sponsor
- Alder Hey Children's NHS Foundation Trust
Chronic Hepatitis C Virus (HCV)
ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-Administered With Ribavirin (RBV) in Treatment Naïve and Treatment Experienced Asian Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated Cirrhosis
This is a Phase 3, open-label, multicenter study evaluating the efficacy and safety of ABT-450/r/ ABT-267 and ABT-333 coadministered with RBV for 12 weeks in HCV genotype 1b, treatment naïve and Interferon (IFN) (alpha, beta or…
- Trial name
- NCT02517528
- Testing
- ABT-450/r/ABT-267, ABT-333, ribavirin
- Volunteers
- 104 people
- Sponsor
- AbbVie
Carcinoma, Colorectal
Phase 1b Dose Escalation Study of Intravenous JX-594 in Metastatic, Refractory Colorectal Carcinoma
The purpose of this pilot safety study is to evaluate the safety and tolerability of JX-594 (Pexa-Vec) administered intravenously every 2 weeks in colorectal carcinoma patients who are refractory to or intolerant of oxaliplatin…
- Trial name
- NCT01380600
- Testing
- Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
- Where
- South Korea
- Volunteers
- 15 people
- Sponsor
- Jennerex Biotherapeutics
Chronic Hepatitis C, Genotype 4 Chronic Hepatitis C
Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Subjects With Chronic Genotype 4 Hepatitis C Virus Infection
The purpose of this study is to show superiority of simeprevir (SMV) in combination with sofosbuvir for 12 weeks versus a historical control.
- Trial name
- NCT02250807
- Testing
- Simeprevir, Sofosbuvir
- Where
- 6 sites in Spain
- Volunteers
- 40 people
- Sponsor
- Janssen R&D Ireland
Hepatitis C
Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C
The purpose of this study is to evaluate the efficacy and safety of telaprevir in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) and ribavirin (RBV) in treatment-experienced Black/African American and…
- Trial name
- NCT01467492
- Testing
- Telaprevir, Ribavirin, Pegylated Interferon Alfa-2a
- Where
- 27 sites in United States
- Volunteers
- 121 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Vaccination Refusal, COVID-19 Pandemic
COVID-19 Messaging for Vaccination
This study will distribute videos of health professionals encouraging Covid-19 vaccination to a large sample of Facebook users, and will test the most effective ways to maximize diffusion of this vaccine-related content to…
- Trial name
- NCT05182554
- Testing
- Doctor Videos, Sharing Videos, Sharing Videos (Influencers)
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Massachusetts Institute of Technology
HIV Infections
The Raltegravir and Ribavirin Pharmacokinetics (PK) Study
The purpose of this study is to look at levels of both a new anti-HIV drug called raltegravir and an existing anti-hepatitis C drug called ribavirin to see if they affect the blood levels of each other when given separately and…
- Trial name
- NCT00982553
- Testing
- Ribavirin, Raltegravir
- Where
- United Kingdom
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Covid19
The Prevent Severe COVID-19 (PRESECO) Study
Double-blinded, placebo control, randomized, phase-3 clinical trial to evaluate clinical efficacy of Favipiravir in patients with mild to moderate symptoms related to COVID-19 infection
- Trial name
- PRESECO (NCT04600895)
- Testing
- Favipiravir
- Where
- 38 sites in United States, Brazil and 1 more
- Volunteers
- 1,187 people
- Sponsor
- Appili Therapeutics Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.